Theravance Biopharma TBPH Accrued General And Administrative Expenses
Accrued General And Administrative Expenses at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:AccruedGeneralAndAdministrativeExpenses.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's accrued general and administrative expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's accrued general and administrative expenses?
- Theravance Biopharma (TBPH) reported accrued general and administrative expenses of $2.52M in Q1 2026.
- How has Theravance Biopharma's accrued general and administrative expenses changed year-over-year?
- Theravance Biopharma's accrued general and administrative expenses increased by 0.1% year-over-year, from $2.52M to $2.52M.
- What is the long-term trend for Theravance Biopharma's accrued general and administrative expenses?
- Over 5 years (2020 to 2025), Theravance Biopharma's accrued general and administrative expenses has grown at a -19.4% compound annual growth rate (CAGR), from $6.05M to $2.05M.
- What does accrued general and administrative expenses mean?
- This represents the short-term liabilities for administrative, legal, and overhead expenses that have been incurred but not yet settled. It serves as a proxy for the company's fixed operational costs and general corporate overhead. Consistent monitoring provides insight into the company's ability to manage its non-research operating expenses.